A Manganese Porphyrin Platform for the Design and Synthesis of Molecular and Targeted MRI Contrast Agents
International Journal of Molecular Sciences · 31.05.2023 · 24 (11) · 9532
DOI: 10.3390/ijms24119532 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.05.2023. Verfasst von Kyle D W Vollett und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada. Hauptthemen laut MEDLINE: Contrast Media, Porphyrins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council, Ted Rogers Centre for Heart Research, Canada Foundation for Innovation.
Abstract (Originalsprache)
Magnetic resonance imaging (MRI) contrast agents, in contrast to the plethora of fluorescent agents available to target disease biomarkers or exogenous implants, have remained predominantly non-specific. That is, they do not preferentially accumulate in specific locations in vivo because doing so necessitates longer contrast retention, which is contraindicated for current gadolinium (Gd) agents. This double-edge sword implies that Gd agents can offer either rapid elimination (but lack specificity) or targeted accumulation (but with toxicity risks). For this reason, MRI contrast agent innovation has been severely constrained. Gd-free alternatives based on manganese (Mn) chelates have been largely ineffective, as they are inherently unstable. In this study, we present a Mn(III) porphyrin (MnP) platform for bioconjugation, offering the highest stability and chemical versatility compared to any other T1 contrast agent. We exploit the inherent metal stability conferred by porphyrins and the absence of pendant bases (found in Gd or Mn chelates) that limit versatile functionalization. As proof-of-principle, we demonstrate labeling of human serum albumin, a model protein, and collagen hydrogels for applications in in-vivo targeted imaging and material tracking, respectively. In-vitro and in-vivo results confirm unprecedented metal stability, ease of functionalization, and high T1 relaxivity. This new platform opens the door to ex-vivo validation by fluorescent imaging and multipurpose molecular imaging in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada.
- Translational Biology & Engineering Program, Ted Rogers Centre for Heart Research, Toronto, ON M5G 1M1, Canada.
- The Edward S. Rogers Sr. Department of Electrical & Computer Engineering, University of Toronto, Toronto, ON M5S 3G8, Canada.
ORCID-Profile: Daniel A Szulc, Hai-Ling Margaret Cheng
Förderung
- Natural Sciences and Engineering Research Council
- Ted Rogers Centre for Heart Research
- Canada Foundation for Innovation
- Dean's Spark Professorship
- Natural Sciences and Engineering Research Council of Canada
- Canada Foundation for Innovation/Ontario Research Fund
- Dean’s Spark Professorship
Zitieren
APA
Vollett, K. D. W., Szulc, D. A., & Cheng, H. M. (2023). A Manganese Porphyrin Platform for the Design and Synthesis of Molecular and Targeted MRI Contrast Agents. International Journal of Molecular Sciences, 24(11), 9532. https://doi.org/10.3390/ijms24119532
Vancouver
Vollett KDW, Szulc DA, Cheng HM. A Manganese Porphyrin Platform for the Design and Synthesis of Molecular and Targeted MRI Contrast Agents. International Journal of Molecular Sciences. 2023;24(11):9532. doi:10.3390/ijms24119532
BibTeX
@article{Vollett2023,
author = {Vollett, Kyle D W and Szulc, Daniel A and Cheng, Hai-Ling Margaret},
title = {A Manganese Porphyrin Platform for the Design and Synthesis of Molecular and Targeted MRI Contrast Agents},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {11},
pages = {9532},
doi = {10.3390/ijms24119532}
}
EUVIMED